Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

Paul Nghiem,Shailender Bhatia,Andrew S. Brohl,Omid Hamid,Janice M. Mehnert,Patrick Terheyden,Kent C. Shih,Isaac Brownell,Celeste Lebbe,Karl D. Lewis,Gerald P. Linette,Michele Milella,Meliessa Hennessy,Marcis Bajars,Christine Hicking,Sandra P. DAngelo

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.

2018

Paul Nghiem
Shailender Bhatia
Andrew S. Brohl
Omid Hamid
Janice M. Mehnert
Patrick Terheyden
Kent C. Shih
Isaac Brownell
Celeste Lebbe
Karl D. Lewis
Gerald P. Linette
Michele Milella
Meliessa Hennessy
Marcis Bajars
Christine Hicking
Sandra P. DAngelo

9507Background: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with poor prognosis. Studies of second-line chemotherapy for metastatic MCC (mMCC) have reported median progression-fre...

Keywords:

Avelumab
Merkel cell carcinoma
Pathology
Javelin
Chemotherapy
Cancer research
Medicine
Skin cancer
Oncology
Internal medicine
poor prognosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations